首页 > 最新文献

Human Antibodies最新文献

英文 中文
Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. SARS-CoV-2 IgG对核衣壳和刺突抗原检测的比较评价。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-210440
Mitra Rezaei, Mohammadhadi Sadeghi, Alireza Korourian, Payam Tabarsi, Mihan Porabdollah, Elham Askari, Esmaeil Mortaz, Shima Mahmoudi, Majid Marjani, Ali Akbar Velayati

Background: There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.

Objective: The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.

Methods: The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens of 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.

Results: Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8+ T cells percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).

Conclusion: Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.

背景:比较抗刺突(S)抗体和抗核蛋白(N)抗体对SARS-CoV-2反应的研究很少。目的:评价病毒S抗原和N抗原IgG抗体的产生及其与发病时间和严重程度的相关性。方法:采用ELISA技术检测72例SARS-CoV-2实时逆转录聚合酶链反应阳性患者血清中SARS-CoV-2 S、N抗原IgG抗体。比较不同抗体反应,并评价与发病时间和严重程度的相关性。结果:72例患者中48例(67%)检测出抗sars - cov -2抗体阳性,24例(33%)未检测到抗体。N抗体和S抗体的抗体水平比较表明,它们之间的相关性很好(r= 0.81;P < 0.001)。而在症状出现后的前7天,抗- s - cov -2 IgG和抗- n - cov -2 IgG的敏感性分别为30%和60% (r= 0.53;P= 0.111),但在症状出现后1周以上分别增加到73%和68% (r= 0.89, P= 0.111)。IgG阳性组CD8+ T细胞百分比较IgG阴性组降低(抗n IgG组为26±14比58±32,p= 0.066;抗s IgG组为28±15比60±45,p= 0.004)。结论:近三分之一的新冠肺炎确诊患者血清学结果为阴性。使用抗s - SARS-COV-2 IgG试剂盒与抗n - SARS-COV-2 IgG相比,在症状出现后(不到1周)的早期时间点的阳性率较低;因此,临床医生应谨慎解释血清学阴性结果,特别是抗SARS-CoV-2 IgG。
{"title":"Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens.","authors":"Mitra Rezaei,&nbsp;Mohammadhadi Sadeghi,&nbsp;Alireza Korourian,&nbsp;Payam Tabarsi,&nbsp;Mihan Porabdollah,&nbsp;Elham Askari,&nbsp;Esmaeil Mortaz,&nbsp;Shima Mahmoudi,&nbsp;Majid Marjani,&nbsp;Ali Akbar Velayati","doi":"10.3233/HAB-210440","DOIUrl":"https://doi.org/10.3233/HAB-210440","url":null,"abstract":"<p><strong>Background: </strong>There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease.</p><p><strong>Methods: </strong>The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens of 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated.</p><p><strong>Results: </strong>Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8+ T cells percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively).</p><p><strong>Conclusion: </strong>Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"109-113"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210440","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25481445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19. COVID-19的全球公共卫生意义、社区卫生保健观念、治疗、预防和控制方法。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200422
Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu

Background: The Novel Coronavirus Disease 2019 (COVID-19) has proved to be one of the most burdensome respiratory disease outbreaks ever. Moreover, the public health emergency of the COVID-19 outbreak has been seen by the World Health Organization (WHO) as global health concern since March 2020 and there has been a significantly increased morbidity and mortality in the community worldwide. The objective of this review is to describe and review the global public health significances and community and healthcare perception of features, treatments, prevention and control methods to slow the transmission of the outbreak.

Methods: For this review, the literature has been searched by following online databases, including medRxiv, pubmed, medline and Google scholar databases. The key search terms 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus' and 'Pneumonia' were used to search the literature. Scientific papers published online by the Center for Disease Control (CDC) and the WHO from 01 January to 06 May 2020 in the English language were included for analysis.

Results: The results of this review indicated that COVID-19 is a serious global public health problem. It affects immune compromised individuals living with chronic diseases, the elderly and pregnant women more severely. The disease spread rapidly from one country to countries worldwide. In all, 212 countries highlighted the weakened state of essential public health and emergency services. The researchers addressed the lack of perception in communities, including health professionals, with regard to COVID-19. Healthcare settings were analyzed in terms of the pandemic nature of the virus, onset and the overall characteristics of disease outbreak. Microbiogists were also used to assess the daily cumulative index of COVID-19. With regard to treatment, chloroquine phosphate and herbal medicines were shown to be promising as supportive treatments to slow COVID-19 transmission, coupled with isolation and quarantine techniques.

Conclusion: The review indicates that COVID-19 has a high global public health significance due to its high morbidity and mortality rates. Still, there was no specific or effective vaccine or treatment, moreover, the community, including health professionals, have a low perception as regards COVID-19, even though different prevention and control methods have been conducted. Thus, there is a need for awareness creation, alongside further research applied to finding effective vaccine and treatments.

背景:2019年新型冠状病毒病(COVID-19)已被证明是有史以来最严重的呼吸道疾病疫情之一。此外,自2020年3月以来,世界卫生组织(世卫组织)将2019冠状病毒病疫情视为全球卫生关注的突发公共卫生事件,全球范围内的发病率和死亡率显著上升。本综述的目的是描述和回顾全球公共卫生意义以及社区和医疗保健对特征、治疗、预防和控制方法的认识,以减缓疫情的传播。方法:本综述通过medRxiv、pubmed、medline和Google scholar等在线数据库进行文献检索。检索关键词为“COVID-19”、“2019 novel coronavirus”、“2019- ncov”、“novel coronavirus”和“Pneumonia”。纳入了2020年1月1日至5月6日期间由美国疾病控制中心(CDC)和世卫组织在线发表的英文科学论文进行分析。结果:本综述结果表明,COVID-19是一个严重的全球性公共卫生问题。它对慢性疾病患者、老年人和孕妇的影响更为严重。这种疾病从一个国家迅速传播到世界各国。总共有212个国家强调了基本公共卫生和应急服务的薄弱状况。研究人员解决了包括卫生专业人员在内的社区对COVID-19缺乏认识的问题。根据病毒的大流行性质、发病情况和疾病暴发的总体特征对医疗保健环境进行了分析。微生物学家还评估了COVID-19的每日累积指数。在治疗方面,磷酸氯喹和草药被证明有希望作为减缓COVID-19传播的支持性治疗,再加上隔离和检疫技术。结论:本文综述表明,新型冠状病毒病具有较高的发病率和死亡率,具有较高的全球公共卫生意义。尽管采取了不同的预防和控制方法,但目前还没有专门有效的疫苗或治疗方法,包括卫生专业人员在内的社会对COVID-19的认知度较低。因此,有必要提高认识,同时进一步开展研究,寻找有效的疫苗和治疗方法。
{"title":"Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19.","authors":"Addis Adera Gebru,&nbsp;Tadesse Birhanu,&nbsp;Eshetu Wendimu,&nbsp;Agumas Fentahun Ayalew,&nbsp;Selamawit Mulat,&nbsp;Hussen Zakir Abasimel,&nbsp;Ali Kazemi,&nbsp;Bosenu Abera Tadesse,&nbsp;Beniam Adera Gebru,&nbsp;Berhanu Senbeta Deriba,&nbsp;Nigus Shimelis Zeleke,&nbsp;Abebe Gule Girma,&nbsp;Bulgantsetseg Munkhbat,&nbsp;Qamar Kassim Yusuf,&nbsp;Amana Ogeto Luke,&nbsp;Dejene Hailu","doi":"10.3233/HAB-200422","DOIUrl":"https://doi.org/10.3233/HAB-200422","url":null,"abstract":"<p><strong>Background: </strong>The Novel Coronavirus Disease 2019 (COVID-19) has proved to be one of the most burdensome respiratory disease outbreaks ever. Moreover, the public health emergency of the COVID-19 outbreak has been seen by the World Health Organization (WHO) as global health concern since March 2020 and there has been a significantly increased morbidity and mortality in the community worldwide. The objective of this review is to describe and review the global public health significances and community and healthcare perception of features, treatments, prevention and control methods to slow the transmission of the outbreak.</p><p><strong>Methods: </strong>For this review, the literature has been searched by following online databases, including medRxiv, pubmed, medline and Google scholar databases. The key search terms 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus' and 'Pneumonia' were used to search the literature. Scientific papers published online by the Center for Disease Control (CDC) and the WHO from 01 January to 06 May 2020 in the English language were included for analysis.</p><p><strong>Results: </strong>The results of this review indicated that COVID-19 is a serious global public health problem. It affects immune compromised individuals living with chronic diseases, the elderly and pregnant women more severely. The disease spread rapidly from one country to countries worldwide. In all, 212 countries highlighted the weakened state of essential public health and emergency services. The researchers addressed the lack of perception in communities, including health professionals, with regard to COVID-19. Healthcare settings were analyzed in terms of the pandemic nature of the virus, onset and the overall characteristics of disease outbreak. Microbiogists were also used to assess the daily cumulative index of COVID-19. With regard to treatment, chloroquine phosphate and herbal medicines were shown to be promising as supportive treatments to slow COVID-19 transmission, coupled with isolation and quarantine techniques.</p><p><strong>Conclusion: </strong>The review indicates that COVID-19 has a high global public health significance due to its high morbidity and mortality rates. Still, there was no specific or effective vaccine or treatment, moreover, the community, including health professionals, have a low perception as regards COVID-19, even though different prevention and control methods have been conducted. Thus, there is a need for awareness creation, alongside further research applied to finding effective vaccine and treatments.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"129-137"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38327229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Global burden of COVID-19: Situational analyis and review. COVID-19全球负担:情况分析和审查。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200420
Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu

Background: The novel Coronavirus Disease 2019 (COVID-19) is the major public health burden in the world. The morbidity and mortality of the global community due to this disease is dramatically increasing from time to time.

Objective: This situational analysis is aimed to analyse prevalence and incidence of COVID-19 and to provide clear information about this disease for the scientific community, stakeholders, healthcare practitioners and decision-makers.

Methods: The literatures were identified by searching the key relevant and officially known online databases: medRxiv, Google scholar and PubMed. The online databases contain archives of most English biomedical journals and scientific papers published online from 31 December to 3 April 2020 were included. After the literature search, articles were screened independently by two reviewers for eligibility.

Results: The world continents have confirmed a total of 1,202,320 confirmed COVID-19 cases: (51.2%) in Europe, (27.7%) in North America, (17.9%) in Asia, (1.96%) in South America and at less number of confirmed COVID-19 cases in Africa and Australia which was accounted 0.8% and 0.5%, respectively. However, this review showed that there was a significant increase in the confirmed COVID-19 cases by 109,555 in Asia, 8,658 in Africa, 332,866 in North America, 20,269 in South America, 568,894 in Europe, 5,051 in Australia and 1,045,403 in the whole world, with the exception of Antartica, during the review period. The overall results showed that there were 1,098,762 cases and 59,172 deaths recorded during the review period. The result zero number of deaths with COVID-19 was observed in 66 countries.

Conclusion: The review concluded that COVID-19; SARS-CoV-2 is the major public health burden in the world, the morbidity and mortality of global community is dramatically increasing from time to time. Strong collaboration among all sectors and the design of effective prevention and control strategies which include staying home, social/physical distancing, quarantine, testing of suspected patients, isolation and managing of the confirmed cases. Therefore, all countries should implement five major COVID-19 prevention and control programmes as soon as possible at community level.

背景:2019年新型冠状病毒病(COVID-19)是全球主要的公共卫生负担。由于这种疾病,全球社会的发病率和死亡率不时急剧增加。目的:本情景分析旨在分析COVID-19的流行和发病率,为科学界、利益相关者、卫生保健从业人员和决策者提供明确的疫情信息。方法:通过检索medRxiv、Google scholar和PubMed等官方知名的关键在线数据库进行文献检索。在线数据库包含了从12月31日至2020年4月3日在线发表的大多数英语生物医学期刊和科学论文的档案。文献检索后,文章由两位审稿人独立筛选。结果:全球各大洲累计确诊病例1202320例,其中欧洲(51.2%)、北美(27.7%)、亚洲(17.9%)、南美(1.96%),非洲和澳大利亚确诊病例较少,分别占0.8%和0.5%。但是,本次审查结果显示,在审查期间,亚洲新增确诊病例109555例,非洲新增确诊病例8658例,北美新增确诊病例332866例,南美新增确诊病例20269例,欧洲新增确诊病例568894例,澳大利亚新增确诊病例5051例,除南极洲外,全球新增确诊病例1045403例。总体结果表明,在审查期间记录了1 098 762例病例和59 172例死亡。结果,66个国家的COVID-19死亡人数为零。结论:综述结论:COVID-19;SARS-CoV-2是世界上主要的公共卫生负担,全球发病率和死亡率不时急剧上升。所有部门之间的密切合作,并制定有效的预防和控制战略,包括呆在家里、保持社交/身体距离、隔离、检测疑似患者、隔离和管理确诊病例。因此,各国应尽快在社区层面实施五大疫情防控规划。
{"title":"Global burden of COVID-19: Situational analyis and review.","authors":"Addis Adera Gebru,&nbsp;Tadesse Birhanu,&nbsp;Eshetu Wendimu,&nbsp;Agumas Fentahun Ayalew,&nbsp;Selamawit Mulat,&nbsp;Hussen Zakir Abasimel,&nbsp;Ali Kazemi,&nbsp;Bosenu Abera Tadesse,&nbsp;Beniam Adera Gebru,&nbsp;Berhanu Senbeta Deriba,&nbsp;Nigus Shimelis Zeleke,&nbsp;Abebe Gule Girma,&nbsp;Bulgantsetseg Munkhbat,&nbsp;Qamar Kassim Yusuf,&nbsp;Amana Ogeto Luke,&nbsp;Dejene Hailu","doi":"10.3233/HAB-200420","DOIUrl":"https://doi.org/10.3233/HAB-200420","url":null,"abstract":"<p><strong>Background: </strong>The novel Coronavirus Disease 2019 (COVID-19) is the major public health burden in the world. The morbidity and mortality of the global community due to this disease is dramatically increasing from time to time.</p><p><strong>Objective: </strong>This situational analysis is aimed to analyse prevalence and incidence of COVID-19 and to provide clear information about this disease for the scientific community, stakeholders, healthcare practitioners and decision-makers.</p><p><strong>Methods: </strong>The literatures were identified by searching the key relevant and officially known online databases: medRxiv, Google scholar and PubMed. The online databases contain archives of most English biomedical journals and scientific papers published online from 31 December to 3 April 2020 were included. After the literature search, articles were screened independently by two reviewers for eligibility.</p><p><strong>Results: </strong>The world continents have confirmed a total of 1,202,320 confirmed COVID-19 cases: (51.2%) in Europe, (27.7%) in North America, (17.9%) in Asia, (1.96%) in South America and at less number of confirmed COVID-19 cases in Africa and Australia which was accounted 0.8% and 0.5%, respectively. However, this review showed that there was a significant increase in the confirmed COVID-19 cases by 109,555 in Asia, 8,658 in Africa, 332,866 in North America, 20,269 in South America, 568,894 in Europe, 5,051 in Australia and 1,045,403 in the whole world, with the exception of Antartica, during the review period. The overall results showed that there were 1,098,762 cases and 59,172 deaths recorded during the review period. The result zero number of deaths with COVID-19 was observed in 66 countries.</p><p><strong>Conclusion: </strong>The review concluded that COVID-19; SARS-CoV-2 is the major public health burden in the world, the morbidity and mortality of global community is dramatically increasing from time to time. Strong collaboration among all sectors and the design of effective prevention and control strategies which include staying home, social/physical distancing, quarantine, testing of suspected patients, isolation and managing of the confirmed cases. Therefore, all countries should implement five major COVID-19 prevention and control programmes as soon as possible at community level.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"139-148"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38269910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
The effect of T helper (Th)/T cytotoxic (Tc) ratio on disease severity in type A hemophilia patients. 辅助T (Th)/T细胞毒(Tc)比值对A型血友病患者病情严重程度的影响
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200434
Hossein Ali Khazaei, Majid Naderi, Ghasem Miri Aliabad, Seyed Mohammad Nasiraldin Tabatabaei, Ali Alidadi, Nezar Ali Moulaei, Mohammad Safdari, Hedayatollah Nahvi, Nader Cohan, Javid Dehghan, Ahmad Mehraban, Arman Jalili, Amin Khazaei, Ehsan Khazaei, Bahman Khazaei, Behnam Khazaei, Nima Rezaei, Morteza Salarzaie, Gholamreza Soleimani

Background and objectives: The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity.

Material and method: Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method.

Results: Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019.

Conclusion: The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender.

背景与目的:本研究的目的是探讨儿童A型血友病患者T辅助(Th)与T细胞毒性(Tc)的比值,并评价该比值与疾病严重程度的相关性。材料与方法:采集EDTA抗凝全血2 ml。使用双CD4和CD8试剂盒,通过FACS分析淋巴细胞计数的免疫表型。计算CD4和CD8淋巴细胞绝对数目/ml的平均值±SD,并采用统计学方法评价CD4/CD8比值。结果:80例A型血友病患者中,男性66例,占82.5%。平均年龄15±3.51岁。其中轻症12例(15%),重症68例(85%)。CD4 /CD8比值在0.45 ~ 1.44之间,平均值为1.79±0.78。该比例与疾病严重程度的相关系数为0.019。结论:A型血友病患者CD4/CD8比值与病情严重程度相关,但与性别无关。
{"title":"The effect of T helper (Th)/T cytotoxic (Tc) ratio on disease severity in type A hemophilia patients.","authors":"Hossein Ali Khazaei,&nbsp;Majid Naderi,&nbsp;Ghasem Miri Aliabad,&nbsp;Seyed Mohammad Nasiraldin Tabatabaei,&nbsp;Ali Alidadi,&nbsp;Nezar Ali Moulaei,&nbsp;Mohammad Safdari,&nbsp;Hedayatollah Nahvi,&nbsp;Nader Cohan,&nbsp;Javid Dehghan,&nbsp;Ahmad Mehraban,&nbsp;Arman Jalili,&nbsp;Amin Khazaei,&nbsp;Ehsan Khazaei,&nbsp;Bahman Khazaei,&nbsp;Behnam Khazaei,&nbsp;Nima Rezaei,&nbsp;Morteza Salarzaie,&nbsp;Gholamreza Soleimani","doi":"10.3233/HAB-200434","DOIUrl":"https://doi.org/10.3233/HAB-200434","url":null,"abstract":"<p><strong>Background and objectives: </strong>The aim of this study was to investigate the T helper (Th) to T cytotoxic (Tc) ratio in children suffering from type A hemophilia disease and to evaluate the correlation of this ratio with disease severity.</p><p><strong>Material and method: </strong>Two mls of EDTA anti coagulated whole blood was collected. Immunophenotyping of lymphocytes count was carried out by FACS analysis using a double CD4 and CD8 kit. The mean ± SD of absolute numbers of CD4 and CD8 lymphocytes/ml was calculated and the ratio of CD4/CD8 was evaluated by statistical method.</p><p><strong>Results: </strong>Among 80 type A hemophilia patients, 66 (82.5%) were male. The mean age was 15 ± 3.51 years. 12 (15%) of them were suffering from mild disease and 68 (85%) had sever disease. The CD4 /CD8 ratio was obtained between 0.45 and 1.44 with mean1.79 ± 0.78. The correlation between this ration and disease severity was 0.019.</p><p><strong>Conclusion: </strong>The results showed that CD4/CD8 ratio has correlation with disease severity in type A hemophilia patients, however there was no association between this ratio and gender.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"95-99"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200434","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38764909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding. 抗神经粘附分子-1抗原干扰成纤维细胞生长因子受体-1结合的人“噬菌体展示”衍生抗体的分离和初步鉴定。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200431
Michela Flego, Gianni Colotti, Alessandro Ascione, Maria Luisa Dupuis, Eleonora Petrucci, Roberta Riccioni, Mauro Andreotti, Carla Raggi, Alessandra Boe, Stefano Barca, Mara Gellini, Stefano Vella, Alessandra Mallano

Background: The NCAM or CD56 antigen is a cell surface glycoprotein belonging to the immunoglobulin super-family involved in cell-cell and cell-matrix adhesion. NCAM is also over-expressed in many tumour types and is considered a tumour associated antigen, even if its role and biological mechanisms implicated in tumour progression and metastasis have not yet to be elucidated. In particular, it is quite well documented the role of the interaction between the NCAM protein and the fibroblast growth factor receptor-1 in metastasis and invasion, especially in the ovarian cancer progression.

Objective: Here we describe the isolation and preliminary characterization of a novel human anti-NCAM single chain Fragment variable antibody able to specifically bind NCAM-expressing cells, including epithelial ovarian cancer cells.

Methods: The antibody was isolate by phage display selection and was characterized by ELISA, FACS analysis and SPR experiments. Interference in EOC migration was analyzed by scratch test.

Results: It binds a partially linear epitope lying in the membrane proximal region of two fibronectin-like domains with a dissociation constant of 3.43 × 10-8 M. Interestingly, it was shown to interfere with the NCAM-FGFR1 binding and to partially decrease migration of EOC cells.

Conclusions: According to our knowledge, this is the first completely human antibody able to interfere with this newly individuated cancer mechanism.

背景:NCAM或CD56抗原是一种细胞表面糖蛋白,属于免疫球蛋白超家族,参与细胞-细胞和细胞-基质的粘附。NCAM在许多肿瘤类型中也过表达,被认为是一种肿瘤相关抗原,尽管其在肿瘤进展和转移中的作用和生物学机制尚未阐明。特别是,NCAM蛋白与成纤维细胞生长因子受体-1之间的相互作用在转移和侵袭中的作用,特别是在卵巢癌的进展中,已经有很好的文献记载。目的:本文描述了一种新型人抗ncam单链片段可变抗体的分离和初步鉴定,该抗体能够特异性结合表达ncam的细胞,包括上皮性卵巢癌细胞。方法:采用噬菌体展示筛选法分离该抗体,采用ELISA、FACS和SPR实验对其进行鉴定。通过划痕试验分析了EOC运移过程中的干扰。结果:它结合位于两个纤维连接蛋白样结构域的膜近端区域的部分线性表位,解离常数为3.43 × 10-8 m。有趣的是,它被证明可以干扰NCAM-FGFR1的结合,并部分减少EOC细胞的迁移。结论:据我们所知,这是第一个能够干扰这种新的个体化癌症机制的完全人类抗体。
{"title":"Isolation and preliminary characterization of a human 'phage display'-derived antibody against neural adhesion molecule-1 antigen interfering with fibroblast growth factor receptor-1 binding.","authors":"Michela Flego,&nbsp;Gianni Colotti,&nbsp;Alessandro Ascione,&nbsp;Maria Luisa Dupuis,&nbsp;Eleonora Petrucci,&nbsp;Roberta Riccioni,&nbsp;Mauro Andreotti,&nbsp;Carla Raggi,&nbsp;Alessandra Boe,&nbsp;Stefano Barca,&nbsp;Mara Gellini,&nbsp;Stefano Vella,&nbsp;Alessandra Mallano","doi":"10.3233/HAB-200431","DOIUrl":"https://doi.org/10.3233/HAB-200431","url":null,"abstract":"<p><strong>Background: </strong>The NCAM or CD56 antigen is a cell surface glycoprotein belonging to the immunoglobulin super-family involved in cell-cell and cell-matrix adhesion. NCAM is also over-expressed in many tumour types and is considered a tumour associated antigen, even if its role and biological mechanisms implicated in tumour progression and metastasis have not yet to be elucidated. In particular, it is quite well documented the role of the interaction between the NCAM protein and the fibroblast growth factor receptor-1 in metastasis and invasion, especially in the ovarian cancer progression.</p><p><strong>Objective: </strong>Here we describe the isolation and preliminary characterization of a novel human anti-NCAM single chain Fragment variable antibody able to specifically bind NCAM-expressing cells, including epithelial ovarian cancer cells.</p><p><strong>Methods: </strong>The antibody was isolate by phage display selection and was characterized by ELISA, FACS analysis and SPR experiments. Interference in EOC migration was analyzed by scratch test.</p><p><strong>Results: </strong>It binds a partially linear epitope lying in the membrane proximal region of two fibronectin-like domains with a dissociation constant of 3.43 × 10-8 M. Interestingly, it was shown to interfere with the NCAM-FGFR1 binding and to partially decrease migration of EOC cells.</p><p><strong>Conclusions: </strong>According to our knowledge, this is the first completely human antibody able to interfere with this newly individuated cancer mechanism.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"63-84"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38584014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Altered expression of STAT genes in periodontitis. 牙周炎中STAT基因表达的改变。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-210444
Leila Gholami, Abolfazl Movafagh, Elham Badrlou, Naghme Nazer, Mohsen Yari, Ghasem Sadeghi, Sara Mirzajani, Mahdi Shadnoush, Arezou Sayad, Soudeh Ghafouri-Fard

Signal Transducer and Activator of Transcription (STAT) pathway is functionally located downstream of Janus kinases proteins and can integrate signals from diverse pathways, thus regulating several aspects of immune responses. Although contribution of STAT proteins in the pathogenesis of several inflammatory conditions has been confirmed, their role in the development of periodontitis has been less appraised. Thus, we assessed levels of STAT transcripts in the periodontal tissues and circulation of affected individuals compared with the corresponding controls. Expression of STAT1 was remarkably lower in tissues samples of patients compared with control tissues (Ratio of mean expression (RME) = 0.15, SE = 0.99, P value = 0.01). Expression of STAT3 was lower in total periodontitis tissues compared with total control tissues (RME = 0.20, SE = 0.95, P value = 0.02). Expression of STAT6 was higher in total periodontitis tissues compared with total control tissues (RME = 0.5.38, SE = 0.74, P value < 0.001). Expressions of other STAT genes were statistically similar in tissues obtained from cases and controls. Moreover, blood levels of all STAT genes were statistically similar between patients and controls. Correlation analysis demonstrated significant correlations between tissues levels of individual STAT genes as well as between their blood levels. However, tissue and blood levels of each STAT gene were not correlated. The current investigation potentiates the role of certain STAT genes in the development of this immune-related condition and warrants functional assays to clarify the mechanism.

信号换能器和转录激活器(Signal Transducer and Activator of Transcription, STAT)通路在功能上位于Janus激酶蛋白的下游,可以整合多种通路的信号,从而调节免疫应答的多个方面。虽然STAT蛋白在几种炎症的发病机制中的作用已经得到证实,但它们在牙周炎发展中的作用却很少得到评价。因此,我们评估了受影响个体的牙周组织和循环中STAT转录本的水平,并与相应的对照进行了比较。STAT1在患者组织样本中的表达明显低于对照组(RME = 0.15, SE = 0.99, P值= 0.01)。STAT3在牙周炎组织中的表达低于对照组(RME = 0.20, SE = 0.95, P值= 0.02)。STAT6在牙周炎总组织中的表达高于对照组(RME = 0.5.38, SE = 0.74, P值< 0.001)。其他STAT基因在病例和对照组织中的表达在统计学上相似。此外,所有STAT基因的血液水平在患者和对照组之间具有统计学上的相似。相关分析表明,个体STAT基因的组织水平之间以及血液水平之间存在显著相关性。然而,组织和血液中每个STAT基因的水平并不相关。目前的研究增强了某些STAT基因在这种免疫相关疾病发展中的作用,并保证了功能分析来阐明其机制。
{"title":"Altered expression of STAT genes in periodontitis.","authors":"Leila Gholami,&nbsp;Abolfazl Movafagh,&nbsp;Elham Badrlou,&nbsp;Naghme Nazer,&nbsp;Mohsen Yari,&nbsp;Ghasem Sadeghi,&nbsp;Sara Mirzajani,&nbsp;Mahdi Shadnoush,&nbsp;Arezou Sayad,&nbsp;Soudeh Ghafouri-Fard","doi":"10.3233/HAB-210444","DOIUrl":"https://doi.org/10.3233/HAB-210444","url":null,"abstract":"<p><p>Signal Transducer and Activator of Transcription (STAT) pathway is functionally located downstream of Janus kinases proteins and can integrate signals from diverse pathways, thus regulating several aspects of immune responses. Although contribution of STAT proteins in the pathogenesis of several inflammatory conditions has been confirmed, their role in the development of periodontitis has been less appraised. Thus, we assessed levels of STAT transcripts in the periodontal tissues and circulation of affected individuals compared with the corresponding controls. Expression of STAT1 was remarkably lower in tissues samples of patients compared with control tissues (Ratio of mean expression (RME) = 0.15, SE = 0.99, P value = 0.01). Expression of STAT3 was lower in total periodontitis tissues compared with total control tissues (RME = 0.20, SE = 0.95, P value = 0.02). Expression of STAT6 was higher in total periodontitis tissues compared with total control tissues (RME = 0.5.38, SE = 0.74, P value < 0.001). Expressions of other STAT genes were statistically similar in tissues obtained from cases and controls. Moreover, blood levels of all STAT genes were statistically similar between patients and controls. Correlation analysis demonstrated significant correlations between tissues levels of individual STAT genes as well as between their blood levels. However, tissue and blood levels of each STAT gene were not correlated. The current investigation potentiates the role of certain STAT genes in the development of this immune-related condition and warrants functional assays to clarify the mechanism.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 3","pages":"209-216"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210444","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39050903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The level of risk, effects response to potential health emergencies, prevention and control method of COVID-19: A systematic review. 2019冠状病毒病风险水平、潜在突发卫生事件应对效果、防控方法综述
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200421
Addis Adera Gebru, Tadesse Birhanu, Eshetu Wendimu, Agumas Fentahun Ayalew, Selamawit Mulat, Hussen Zakir Abasimel, Ali Kazemi, Bosenu Abera Tadesse, Beniam Adera Gebru, Berhanu Senbeta Deriba, Nigus Shimelis Zeleke, Abebe Gule Girma, Bulgantsetseg Munkhbat, Qamar Kassim Yusuf, Amana Ogeto Luke, Dejene Hailu

Background: COVID-19 is currently the major public health burden in the world, with disease and death in the global community from COVID-19 increasing rapidly from time to time worldwide. However, there has been a lack of well-organized information about the level of risk, effects, prevention and control methods of the disease. Therefore the aim of this study is to identify and review a published level of risk, effects response to potential health emergencies, prevention, and control methods of COVID-19 at a global level.

Method: A systematic review was performed after literatures were identified by searching the following online databases: medRxiv, Google scholar, PubMed, MEDLINE, EMBASE, and the Cochrane Library with supplementary hand searching of conferences. The online databases contain archives of most English biomedical journals. Scientific papers published online by the Center for Disease Control and the World Health Organization were also included for this analysis. The scientific publications from 01 December, 2019 to 13 April 2020 were included. The 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus', and 'Pneumonia' key search terms were used for this review.

背景:COVID-19是目前世界上主要的公共卫生负担,全球范围内因COVID-19引起的疾病和死亡人数不时迅速增加。然而,缺乏关于该疾病的风险程度、影响、预防和控制方法的组织良好的信息。因此,本研究的目的是在全球范围内确定和审查已公布的COVID-19风险水平、对潜在卫生突发事件的影响响应以及预防和控制方法。方法:通过检索medRxiv、Google scholar、PubMed、MEDLINE、EMBASE和Cochrane Library等在线数据库,并辅以手工检索会议,对文献进行系统评价。在线数据库包含大多数英文生物医学期刊的档案。疾病控制中心和世界卫生组织在网上发表的科学论文也被纳入了这项分析。纳入了2019年12月1日至2020年4月13日的科学出版物。“COVID-19”、“2019新型冠状病毒”、“2019- ncov”、“新型冠状病毒”和“肺炎”关键搜索词被用于本综述。
{"title":"The level of risk, effects response to potential health emergencies, prevention and control method of COVID-19: A systematic review.","authors":"Addis Adera Gebru,&nbsp;Tadesse Birhanu,&nbsp;Eshetu Wendimu,&nbsp;Agumas Fentahun Ayalew,&nbsp;Selamawit Mulat,&nbsp;Hussen Zakir Abasimel,&nbsp;Ali Kazemi,&nbsp;Bosenu Abera Tadesse,&nbsp;Beniam Adera Gebru,&nbsp;Berhanu Senbeta Deriba,&nbsp;Nigus Shimelis Zeleke,&nbsp;Abebe Gule Girma,&nbsp;Bulgantsetseg Munkhbat,&nbsp;Qamar Kassim Yusuf,&nbsp;Amana Ogeto Luke,&nbsp;Dejene Hailu","doi":"10.3233/HAB-200421","DOIUrl":"https://doi.org/10.3233/HAB-200421","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 is currently the major public health burden in the world, with disease and death in the global community from COVID-19 increasing rapidly from time to time worldwide. However, there has been a lack of well-organized information about the level of risk, effects, prevention and control methods of the disease. Therefore the aim of this study is to identify and review a published level of risk, effects response to potential health emergencies, prevention, and control methods of COVID-19 at a global level.</p><p><strong>Method: </strong>A systematic review was performed after literatures were identified by searching the following online databases: medRxiv, Google scholar, PubMed, MEDLINE, EMBASE, and the Cochrane Library with supplementary hand searching of conferences. The online databases contain archives of most English biomedical journals. Scientific papers published online by the Center for Disease Control and the World Health Organization were also included for this analysis. The scientific publications from 01 December, 2019 to 13 April 2020 were included. The 'COVID-19', '2019 novel coronavirus', '2019-nCoV', 'novel coronavirus', and 'Pneumonia' key search terms were used for this review.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 2","pages":"149-169"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200421","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38327228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients. 循环巨噬细胞炎症蛋白-1β/IL-12p40比值预测HCV-基因型4患者索非布韦治疗结果
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-211504
Heba Shawky, Reem El-Shenawy, Naiera M Helmy

This study aimed to evaluate the prognostic value of baseline macrophage inflammatory protein (MIP)-1β/IL12p40 ratio for antiviral treatment outcome in HCV genotype 4 patients.

Methods: Sera of 450 treatment-naïve chronic HCV patients and 50 healthy individuals were collected. Liver transaminases, total bilirubin and albumin were biochemically tested, viral RNA was quantified, and circulating MIP-1β and IL-12p40 were estimated using human anti-MIP-1β and IL-12p40 antibodies in Sandwich ELISA.

Results: No difference was observed in the baseline chemokines levels between responders and relapsers, but the later had a significantly higher MIP-1β/IL-12p40 ratio (P< 0.0001). Multivariate regression analysis of baseline characteristics showed that gender, age, viral load, albumin level and chemokine ratios can significantly predict treatment outcome (P= 0.0114, 0.0095, 0.042, 0.0004 and < 0.0001; respectively). Accordingly, a predictive threshold of baseline chemokine ratio was calculated and it showed an AUC of 0.6917 (P= 0.0108; 95% CI: 0.5566 to 0.8268). The calculated threshold for predicting virologic response was 8.245, with positive and negative predictive values of 92.98% and 100%; respectively. The chemokine ratios had significant correlations with liver transaminases in treated groups whether pre or post-treatment.

Conclusion: Baseline MIP-1β/IL-12p40 ratio represents a non-invasive prognostic biomarker that would provide shorter treatment duration and minimizes the emergence of drug-resistant variants in HCV genotype 4-patients.

本研究旨在评估基线巨噬细胞炎症蛋白(MIP)-1β/IL12p40比值对HCV基因型4患者抗病毒治疗结果的预后价值。方法:收集450例treatment-naïve慢性HCV患者和50例健康人的血清。采用Sandwich ELISA法检测肝脏转氨酶、总胆红素和白蛋白,定量检测病毒RNA,检测循环MIP-1β和IL-12p40抗体。结果:缓解者和复发者的基线趋化因子水平无差异,但复发者的MIP-1β/IL-12p40比值显著高于缓解者(P< 0.0001)。基线特征的多因素回归分析显示,性别、年龄、病毒载量、白蛋白水平和趋化因子比值能显著预测治疗结果(P= 0.0114、0.0095、0.042、0.0004和< 0.0001;分别)。据此,计算基线趋化因子比值的预测阈值,AUC为0.6917 (P= 0.0108;95% CI: 0.5566 ~ 0.8268)。预测病毒学反应的计算阈值为8.245,阳性预测值为92.98%,阴性预测值为100%;分别。治疗前后各组趋化因子比值与肝转氨酶有显著相关性。结论:基线MIP-1β/IL-12p40比值是一种非侵入性预后生物标志物,可缩短HCV基因型4患者的治疗时间,并最大限度地减少耐药变异的出现。
{"title":"Circulating macrophage inflammatory protein-1β/IL-12p40 ratio predicts sofosbuvir-based treatment outcome in HCV- genotype 4 patients.","authors":"Heba Shawky,&nbsp;Reem El-Shenawy,&nbsp;Naiera M Helmy","doi":"10.3233/HAB-211504","DOIUrl":"https://doi.org/10.3233/HAB-211504","url":null,"abstract":"<p><p>This study aimed to evaluate the prognostic value of baseline macrophage inflammatory protein (MIP)-1β/IL12p40 ratio for antiviral treatment outcome in HCV genotype 4 patients.</p><p><strong>Methods: </strong>Sera of 450 treatment-naïve chronic HCV patients and 50 healthy individuals were collected. Liver transaminases, total bilirubin and albumin were biochemically tested, viral RNA was quantified, and circulating MIP-1β and IL-12p40 were estimated using human anti-MIP-1β and IL-12p40 antibodies in Sandwich ELISA.</p><p><strong>Results: </strong>No difference was observed in the baseline chemokines levels between responders and relapsers, but the later had a significantly higher MIP-1β/IL-12p40 ratio (P< 0.0001). Multivariate regression analysis of baseline characteristics showed that gender, age, viral load, albumin level and chemokine ratios can significantly predict treatment outcome (P= 0.0114, 0.0095, 0.042, 0.0004 and < 0.0001; respectively). Accordingly, a predictive threshold of baseline chemokine ratio was calculated and it showed an AUC of 0.6917 (P= 0.0108; 95% CI: 0.5566 to 0.8268). The calculated threshold for predicting virologic response was 8.245, with positive and negative predictive values of 92.98% and 100%; respectively. The chemokine ratios had significant correlations with liver transaminases in treated groups whether pre or post-treatment.</p><p><strong>Conclusion: </strong>Baseline MIP-1β/IL-12p40 ratio represents a non-invasive prognostic biomarker that would provide shorter treatment duration and minimizes the emergence of drug-resistant variants in HCV genotype 4-patients.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 4","pages":"263-274"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39407675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral hospital-based study. 儿童患者SARS-CoV-2抗体检测:一项基于伊朗转诊医院的研究
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-210448
Setareh Mamishi, Golnaz Ghazizadeh Esslami, Mohsen Mohammadi, Mohammad Reza Abdolsalehi, Reihaneh Hosseinpour Sadeghi, Shima Mahmoudi, Babak Pourakbari

Background: As the extent of the pandemic and its seroprevalence pattern has been less clarified in pediatrics to date, we aimed to conduct this study to investigate the clinical and laboratory characteristics of COVID-19 in Iranian children, with a focus on evaluating the antibody prevalence and its relation with the laboratory tests.

Methods: All children with highly suspected COVID-19 were included. Anti-nucleoprotein SARS-CoV-2 were measured using SARS-CoV-2 immunoglobulin M (IgM) and SARS-CoV-2 IgG ELISA kits. Hypothesis testing was carried out through SPSS to unravel any association between the measurement tools and important clinical and laboratory characteristics.

Results: In this study, 254 patients were evaluated and 117 cases (46%) were male. The nucleic acid detection results for patient 55 were negative, but the IgM and IgG results were positive. Totally, 190 patients were tested for IgM in which only 14 (7.3%) had positive tests. Positive IgG was detected in 51 (20%) out of 254 patients; among them, 30 patients had negative SARS-CoV-2 RT-PCR (59%). Lower level of platelets in IgG positive group in comparison with the IgG negative group was observed (P value: 0.015). Moreover, higher alanine aminotransferase (ALT) was observed in the in IgG positive group (P value: 0.02). In patients with positive IgM, relative hypocalcemia (median of 8.25; IQR: 8.02-8.62) was found which appeared to be significant (P value: 0.02).

Conclusion: This is the first largest study describing the SARS-CoV-2 seropositivity among children in Iran and provides important insight about the COVID-19 infection in children.

背景:由于迄今为止在儿科中大流行的程度及其血清阳性率模式尚不清楚,我们旨在开展本研究,调查伊朗儿童COVID-19的临床和实验室特征,重点评估抗体流行率及其与实验室检测的关系。方法:纳入所有高度疑似COVID-19患儿。采用SARS-CoV-2免疫球蛋白M (IgM)和SARS-CoV-2 IgG ELISA试剂盒检测SARS-CoV-2抗核蛋白水平。通过SPSS进行假设检验,以揭示测量工具与重要临床和实验室特征之间的任何关联。结果:本研究共评估254例患者,其中男性117例(46%)。55例患者核酸检测结果为阴性,但IgM和IgG结果为阳性。总共有190例患者接受了IgM检测,其中只有14例(7.3%)呈阳性。254例患者中IgG阳性51例(20%);其中SARS-CoV-2 RT-PCR阴性30例(59%)。IgG阳性组血小板水平低于IgG阴性组(P值:0.015)。IgG阳性组丙氨酸转氨酶(ALT)升高(P值:0.02)。在IgM阳性的患者中,相对低钙(中位数为8.25;IQR: 8.02-8.62),差异有统计学意义(P值:0.02)。结论:这是首个描述伊朗儿童SARS-CoV-2血清阳性的大型研究,为了解儿童COVID-19感染提供了重要见解。
{"title":"Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral hospital-based study.","authors":"Setareh Mamishi,&nbsp;Golnaz Ghazizadeh Esslami,&nbsp;Mohsen Mohammadi,&nbsp;Mohammad Reza Abdolsalehi,&nbsp;Reihaneh Hosseinpour Sadeghi,&nbsp;Shima Mahmoudi,&nbsp;Babak Pourakbari","doi":"10.3233/HAB-210448","DOIUrl":"https://doi.org/10.3233/HAB-210448","url":null,"abstract":"<p><strong>Background: </strong>As the extent of the pandemic and its seroprevalence pattern has been less clarified in pediatrics to date, we aimed to conduct this study to investigate the clinical and laboratory characteristics of COVID-19 in Iranian children, with a focus on evaluating the antibody prevalence and its relation with the laboratory tests.</p><p><strong>Methods: </strong>All children with highly suspected COVID-19 were included. Anti-nucleoprotein SARS-CoV-2 were measured using SARS-CoV-2 immunoglobulin M (IgM) and SARS-CoV-2 IgG ELISA kits. Hypothesis testing was carried out through SPSS to unravel any association between the measurement tools and important clinical and laboratory characteristics.</p><p><strong>Results: </strong>In this study, 254 patients were evaluated and 117 cases (46%) were male. The nucleic acid detection results for patient 55 were negative, but the IgM and IgG results were positive. Totally, 190 patients were tested for IgM in which only 14 (7.3%) had positive tests. Positive IgG was detected in 51 (20%) out of 254 patients; among them, 30 patients had negative SARS-CoV-2 RT-PCR (59%). Lower level of platelets in IgG positive group in comparison with the IgG negative group was observed (P value: 0.015). Moreover, higher alanine aminotransferase (ALT) was observed in the in IgG positive group (P value: 0.02). In patients with positive IgM, relative hypocalcemia (median of 8.25; IQR: 8.02-8.62) was found which appeared to be significant (P value: 0.02).</p><p><strong>Conclusion: </strong>This is the first largest study describing the SARS-CoV-2 seropositivity among children in Iran and provides important insight about the COVID-19 infection in children.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 3","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-210448","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39251786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Hypolipidemic effects of Hypericum Scabrum extract on the serum lipid profile and obesity in high-fat diet fed rats. 金丝桃提取物对高脂饲粮大鼠血脂及肥胖的降血脂作用。
Q3 Medicine Pub Date : 2021-01-01 DOI: 10.3233/HAB-200430
Nafiseh Faraji, Ahmad Ganji, Neda Heshami, Iraj Salehi, Ahmad Haddadian, Shiva Shojaie, Alireza Komaki

Diets included high-fat (HFD) and high calories intake is correlated with greater risk of obesity and oxidative stress, which lead to increase the risk of related diseases such as cardiovascular and metabolic disease. In the present study, we have examined the hypolipidemic activity of Hypericum Scabrum extract on HFD fed rats. Fifty-four male Wistar rats divided into six groups: 1) control, 2) H. Scabrum extract (100 mg/kg gavage per day), 3) H. Scabrum extract (300 mg/kg), 4) HFD, 5) HFD and H. Scabrum extract (100 mg/kg), 6) HFD and H. Scabrum extract (300 mg/kg). The groups were fed their diet and treatment for 3 months. Biochemical analysis showed elevated lipid serum profile in HFD rats compared to control group. H. Scabrum extract supplementation significantly ameliorated triglyceride, total cholesterol and LDL-cholesterol. H. Scabrum extract supplementation leading to increase HDL-cholesterol in HFD treated groups. This experiment showed that H. Scabrum extract decreased HFD complications and might be beneficial herbal drug for treatment of hyperlipidemia and obesity.

高脂肪(HFD)和高卡路里的饮食摄入与肥胖和氧化应激的风险增加相关,从而导致心血管和代谢疾病等相关疾病的风险增加。在本研究中,我们检测了金丝桃提取物对HFD喂养大鼠的降血脂活性。雄性Wistar大鼠54只,随机分为6组:1)对照组,2)黄芩提取物(每天灌胃100 mg/kg), 3)黄芩提取物(300 mg/kg), 4) HFD, 5) HFD +黄芩提取物(100 mg/kg), 6) HFD +黄芩提取物(300 mg/kg)。各组按上述方法饲喂饲粮和治疗3个月。生化分析显示,与对照组相比,HFD大鼠血清脂质谱升高。皂荚提取物补充显著改善甘油三酯,总胆固醇和低密度脂蛋白胆固醇。在HFD处理组中,补充剑鞘提取物导致hdl -胆固醇升高。本实验表明,苦参提取物可降低HFD并发症,可能是治疗高脂血症和肥胖症的有益中药。
{"title":"Hypolipidemic effects of Hypericum Scabrum extract on the serum lipid profile and obesity in high-fat diet fed rats.","authors":"Nafiseh Faraji,&nbsp;Ahmad Ganji,&nbsp;Neda Heshami,&nbsp;Iraj Salehi,&nbsp;Ahmad Haddadian,&nbsp;Shiva Shojaie,&nbsp;Alireza Komaki","doi":"10.3233/HAB-200430","DOIUrl":"https://doi.org/10.3233/HAB-200430","url":null,"abstract":"<p><p>Diets included high-fat (HFD) and high calories intake is correlated with greater risk of obesity and oxidative stress, which lead to increase the risk of related diseases such as cardiovascular and metabolic disease. In the present study, we have examined the hypolipidemic activity of Hypericum Scabrum extract on HFD fed rats. Fifty-four male Wistar rats divided into six groups: 1) control, 2) H. Scabrum extract (100 mg/kg gavage per day), 3) H. Scabrum extract (300 mg/kg), 4) HFD, 5) HFD and H. Scabrum extract (100 mg/kg), 6) HFD and H. Scabrum extract (300 mg/kg). The groups were fed their diet and treatment for 3 months. Biochemical analysis showed elevated lipid serum profile in HFD rats compared to control group. H. Scabrum extract supplementation significantly ameliorated triglyceride, total cholesterol and LDL-cholesterol. H. Scabrum extract supplementation leading to increase HDL-cholesterol in HFD treated groups. This experiment showed that H. Scabrum extract decreased HFD complications and might be beneficial herbal drug for treatment of hyperlipidemia and obesity.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"29 1","pages":"55-61"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/HAB-200430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38556390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Human Antibodies
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1